Real-time biomedical studies of factors leading to vision impairment are now possible through one of the world's largest ocular research centre at Lions Eye Institute for Transplant & Research.
Real-time biomedical studies of factors leading to vision impairment are now possible through one of the world's largest ocular research centre at Lions Eye Institute for Transplant & Research. As the first research centre in the world to be directly combined with an eye bank, the Ocular Research Centre provides a repository of healthy and diseased ocular tissue for researchers from academic institutions, government organizations and the pharmaceutical industry.
For the first time, researchers can study the complete picture of health through tissue, medical history and family information, which will improve the understanding of underlying health factors leading to vision impairment and blindness. These studies will drive the development of new diagnostic tests and pharmacologic treatments for delaying, stopping and preventing progression of ocular diseases and conditions.
Over the past 30 years, Lions Eye Institute for Transplant & Research has provided 50,000 eyes for research and given the gift of sight through cornea transplantation to more than 30,000 men, women and children worldwide.The Ocular Research Centre recently established a relationship with Emory University and we look forward to forming relationships with other organizations to accelerate drug innovation, provide timely clinical trials and formalize best practices, said Jason Woody, Lions Eye Institute for Transplant & Research CEO.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.